We report an analysis of in vitro growth characteristics of leukaemic
cells from five patients with t(6;9)(p23;q34). Consistent with other r
eports of this abnormality, our patients were comparatively young (med
ian age at diagnosis, 29 years), and responded poorly to conventional
treatment (median survival from diagnosis, 10 months). During active d
isease the CFU-GM growth patterns were characterized by an abundance o
f granulocytic aggregates (mostly 20-100 cells in size) whose leukaemi
c origin was confirmed by cytogenetic analysis. During remission induc
tion, colonies derived from regenerating normal progenitor cells colon
ies could be distinguished from those derived from persisting leukaemi
c cells on the basis of differences in size, morphology, in situ stain
ing characteristics, and karyotype. Remission growth patterns were tho
se of a normal bone marrow. Our findings add to a growing recognition
that the t(6;9) identifies a subset of leukaemic patients with distinc
tive clinical, haematologic, molecular, and in vitro growth characteri
stics for whom conventional treatment offers little hope of cure or lo
ng survival.